Patent · US Active

PRAME peptide analogues

US7511119B2 · kind B2 · utility

6Cited by
18References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 16, 2006
Grant dateMar 31, 2009
Priority date
Expiry dateJun 16, 2026

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/645
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.